The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
MANIFEST-2 updated results: Pelabresib plus ruxolitinib in JAKi-naïve patients with MF
|
Pelabresib is an oral, small-molecule BET inhibitor capable of modifying critical components of MF pathobiology. Updated results from the MANIFEST-2 trial (NCT04603495) evaluating the long-term efficacy and safety of pelabresib + ruxolitinib vs ruxolitinib + placebo in JAKi-naïve patients with MF were presented by John Mascarenhas at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
| A higher proportion of patients receiving PELA + RUX arm achieved SVR35 responses at Week 48 vs those receiving RUX + PBO (57.0% vs 37.5%). |
| At Week 48, TSS50 responses were achieved by 45.3% vs 39.4% of patients receiving PELA + RUX vs RUX + PBO, respectively. Grade ≥1 BM fibrosis improvement was higher with PELA + RUX vs RUX + PBO (41.0% vs 15.0%). |
| Hb responses were achieved by 13.1% and 7.9% of patients receiving PELA + RUX vs RUX + PBO, respectively. Grade ≥3 anemia was reported in 25.9% vs 38.3% of patients in the PELA + RUX vs RUX + PBO arms, respectively. |
| These findings suggest that PELA + RUX results in deep and sustained responses and continues to improve outcomes in JAKi-naïve patients with MF. Longer-term follow-up results will be presented at future conferences. |
Abbreviations: ASH, American Society of Hematology; BET, bromodomain and extra-terminal; BM, bone marrow; Hb, hemoglobin; JAKi, Janus kinase inhibitor; MF, myelofibrosis; PELA, pelabresib; PBO, placebo; RUX, ruxolitinib; SVR35, spleen volume reduction ≥35%; TSS, total symptom score.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
